Research progress of KRASG12C inhibitors in the treatment of advanced colorectal cancer

doi:10.3760/cma.j.cn371439-20250225-00091

Abstract

Abstract:

Colorectal cancer （CRC） remains a leading cause of cancer mortality globally. Mutations of the KRAS gene occur in 30%-40% of metastatic colorectal cancer patients， contributing to resistance to anti-epidermal growth factor receptor therapy and poor prognosis. Targeted therapy for KRAS has always been a research hotspot. In recent years， KRAS^G12C mutation inhibitors have achieved good efficacy in the treatment of solid tumors. KRAS^G12C inhibitors can be used as monotherapies and in combination with other targeted inhibitors for metastatic KRAS^G12C-mutant colorectal cancer. Analyzing the research progress of KRAS^G12C inhibitors in CRC is of great significance and can provide reference for guiding the treatment of advanced CRC.

Key words: Colorectal neoplasms, KRAS^G12C inhibitors, Molecular targete therapy

Wu Xin, Ren Haipeng. Research progress of KRAS^G12C inhibitors in the treatment of advanced colorectal cancer[J]. Journal of International Oncology, 2025, 52(8): 538-542.

References 39

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708.
[3]	Henry JT, Coker O, Chowdhury S, et al. Comprehensive clinical and molecular characterization of KRAS^G12C-mutant colorectal cancer[J]. JCO Precis Oncol, 2021, 5: PO. 20.00256. DOI: 10.1200/PO.20.00256.
[4]	Loong HH, Du N, Cheng C, et al. KRAS^G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples[J]. Transl Lung Cancer Res, 2020, 9(5): 1759-1769. DOI: 10.21037/tlcr-20-455.
[5]	Hong DS, Fakih MG, Strickler JH, et al. KRAS^G12C inhibition with sotorasib in advanced solid tumors[J]. N Engl J Med, 2020, 383(13): 1207-1217. DOI: 10.1056/NEJMoa1917239.
[6]	Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS^G12C[J]. N Engl J Med, 2023, 388(1): 44-54. DOI: 10.1056/NEJMoa2212419.
[7]	Jiang J, Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers[J]. Cancer Discov, 2024, 14(6): 994-1017. DOI: 10.1158/2159-8290.CD-24-0027.
[8]	Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance[J]. J Cell Sci, 2016, 129(7): 1287-1292. DOI: 10.1242/jcs.182873.
[9]	Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635. DOI: 10.1016/j.cell.2017.07.029.
[10]	Yuan TL, Amzallag A, Bagni R, et al. Differential effector engagement by oncogenic KRAS[J]. Cell Rep, 2018, 22(7): 1889-1902. DOI: 10.1016/j.celrep.2018.01.051.
[11]	Takeda M, Yoshida S, Inoue T, et al. The role of KRAS mutations in colorectal cancer: biological insights, clinical implications, and future therapeutic perspectives[J]. Cancers (Basel), 2025, 17(3): 428. DOI: 10.3390/cancers17030428.
[12]	Papke B, Der CJ. Drugging RAS: know the enemy[J]. Science, 2017, 355(6330): 1158-1163. DOI: 10.1126/science.aam7622.
[13]	Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions[J]. Nature, 2013, 503(7477): 548-551. DOI: 10.1038/nature12796.
[14]	Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance[J]. Cancer Gene Ther, 2022, 29(7): 875-878. DOI: 10.1038/s41417-021-00383-9.
[15]	Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRAS^G12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial[J]. Lancet Oncol, 2022, 23(1): 115-124. DOI: 10.1016/S1470-2045(21)00605-7.
[16]	Ou SI, Jänne PA, Leal TA, et al. First-in-human phase Ⅰ/ⅠB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS^G12C solid tumors (KRYSTAL-1)[J]. J Clin Oncol, 2022, 40(23): 2530-2538. DOI: 10.1200/JCO.21.02752.
[17]	Hallin J, Engstrom LD, Hargis L, et al. The KRAS^G12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J]. Cancer Discov, 2020, 10(1): 54-71. DOI: 10.1158/2159-8290.CD-19-1167.
[18]	Sacher A, LoRusso P, Patel MR, et al. Single-agent divarasib(GDC-6036) in solid tumors with a KRAS^G12C mutation[J]. N Engl J Med, 2023, 389(8): 710-721. DOI: 10.1056/NEJMoa2303810.
[19]	Zhou Q, Meng X, Sun L, et al. Efficacy and safety of KRAS^G12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study[J]. J Thorac Oncol, 2024, 19(12): 1630-1639. DOI: 10.1016/j.jtho.2024.08.005.
[20]	ClinicalTrials. Gov. An open-label, multi-center phase Ⅰ/Ⅱ clinical study evaluating the safety/tolerability, pharmacokinetics, and effectiveness of GFH925 in patients with advanced solid tumors with KRAS^G12C mutations[EB/OL]. [2024-11-26] [2025-04-08]. https://adisinsight.springer.com/trials/700341538.
[21]	ClinicalTrials. Gov. An open-label, multicenter, phase Ⅰb/Ⅲ study of efficacy and safety of IBI351 in combination with cetuximab in subjects with KRAS^G12C mutated metastatic colorectal cancer[EB/OL]. [2022-09-30] [2025-04-08]. https://clinicaltrials.gov/study/NCT05497336?term=NCT05497336&rank=1.
[22]	Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS^G12C inhibition in colorectal cancer[J]. Cancer Discov, 2020, 10(8): 1129-1139. DOI: 10.1158/2159-8290.CD-20-0187.
[23]	Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRAS^G12C-EGFR inhibition in colorectal cancer[J]. Cancer Discov, 2023, 13(1): 41-55. DOI: 10.1158/2159-8290.CD-22-0405.
[24]	Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS^G12C[J]. N Engl J Med, 2023, 389(23): 2125-2139. DOI: 10.1056/NEJMoa2308795.
[25]	Yaeger R, Uboha NV, Pelster MS, et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRAS^G12C-mutated metastatic colorectal cancer[J]. Cancer Discov, 2024, 14(6): 982-993. DOI: 10.1158/2159-8290.CD-24-0217.
[26]	Desai J, Alonso G, Kim SH, et al. Divarasib plus cetuximab in KRAS^G12C-positive colorectal cancer: a phase 1b trial[J]. Nat Med, 2024, 30(1): 271-278. DOI: 10.1038/s41591-023-02696-8.
[27]	ClinicalTrials. Gov. A phase 1/1b trial of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRAS^G12C mutation[EB/OL]. [2024-12-16] [2025-02-28]. https://clinicaltrials.gov/study/NCT04975256?term=NCT04975256&rank=1.
[28]	ClinicalTrials. Gov. A phase 1/2 trial of MRTX849 in combination with TNO155 in patients with advanced solid tumors with KRAS^G12C mutation KRYSTAL 2[EB/OL]. [2025-04-04] [2025-04-07]. https://clinicaltrials.gov/study/NCT04330664?term=NCT04330664&rank=1.
[29]	ClinicalTrials. Gov. Phase Ⅰ trial of adagrasib (MRTX849) in combination with cetuximab and irinotecan in patients with colorectal cancer[EB/OL]. [2025-03-10] [2025-04-07]. https://clinicaltrials.gov/study/NCT05722327?term=NCT05722327&rank=1.
[30]	ClinicalTrials. Gov. Study of sotorasib, panitumumab and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for treatment-naïve subjects with metastatic colorectal cancer with KRAS p.G12C mutation (CodeBreaK 301)[EB/OL]. [2025-04-04] [2025-04-07]. https://clinicaltrials.gov/study/NCT06252649?term=NCT06252649&rank=1.
[31]	Zhang J, Lim SM, Yu MR, et al. D3S-001, a KRAS^G12Cinhibitor with rapid target engagement kinetics, overcomes nucleotide cycling, and demonstrates robust preclinical and clinical activities[J]. Cancer Discov, 2024, 14(9): 1675-1698. DOI: 10.1158/2159-8290.CD-24-0006.
[32]	ClinicalTrials. Gov. A Phase 1/2, open label, dose-escalation, and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S 001 monotherapy or combination therapy in subjects with advanced solid tumors with a KRAS p.G12C mutation[EB/OL]. [2025-04-08] [2025-04-08]. https://clinicaltrials.gov/study/NCT05410145?term=NCT05410145&rank=1.
[33]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98. DOI: 10.3760/cma.j.cn371439-20231008-00013.
[34]	Stickler S, Rath B, Hamilton G. Targeting KRAS in pancreatic cancer[J]. Oncol Res, 2024, 32(5): 799-805. DOI: 10.32604/or.2024.045356.
[35]	Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms[J]. J Hematol Oncol, 2024, 17(1): 108. DOI: 10.1186/s13045-024-01631-9.
[36]	Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS^G12C inhibition in cancer[J]. N Engl J Med, 2021, 384(25): 2382-2393. DOI: 10.1056/NEJMoa2105281.
[37]	Ryan MB, Coker O, Sorokin A, et al. KRAS^G12C-independent feedback activation of wild-type RAS constrains KRAS^G12C inhibitor efficacy[J]. Cell Rep, 2022, 39(12): 110993. DOI: 10.1016/j.celrep.2022.110993.
[38]	Paniagua G, Jacob HKC, Brehey O, et al. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors[J]. Mol Oncol, 2022, 16(17): 3066-3081. DOI: 10.1002/1878-0261.13213.
[39]	Hu F, Lito P. Insights into how adeno-squamous transition drives KRAS inhibitor resistance[J]. Cancer Cell, 2024, 42(3): 330-332. DOI: 10.1016/j.ccell.2024.02.014.

Research progress of KRAS^G12C inhibitors in the treatment of advanced colorectal cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 39

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Jun, Tang Dandan, Zhou Yuxin, Tan Yuting, Li Honglan, Xu Qun, Xiang Yongbing. Time trend analysis of the disease burden of colorectal cancer among young and middle-aged adults in China from 1990 to 2021 [J]. Journal of International Oncology, 2025, 52(8): 508-516.
[2]	Wang Yong, Wu Xinlin. Related molecular mechanisms of liver metastasis from colorectal cancer [J]. Journal of International Oncology, 2025, 52(6): 388-391.
[3]	Guo Haiyang, Hong Yonggang, Hao Liqiang. Role and research progress of ferroptosis in colorectal cancer [J]. Journal of International Oncology, 2025, 52(5): 319-324.
[4]	Wang Yi, Wang Qiangli, Zhang Jia, Yang Yijin, Wang Sheng. Relationship between the expression of SUCNR1 and YBX1 in tissues of patients with colorectal cancer liver metastases and their clinicopathological characteristics and prognosis [J]. Journal of International Oncology, 2025, 52(3): 152-157.
[5]	Zhan Haifeng, Tan Zixuan, Wang Wenxue, Geng Jiawei. Research progress of circadian genes in the occurrence， development and chronotherapy of colorectal cancer [J]. Journal of International Oncology, 2025, 52(1): 60-64.
[6]	Wei Wei, Cai Zhaoying, Qian Yayun. Effect of Marsdenia tenacissima combined with XELOX solution on disulfide apoptosis in human colorectal cancer HCT116 cells [J]. Journal of International Oncology, 2024, 51(9): 545-555.
[7]	Zhan Haifeng, Wang Wenxue, Geng Jiawei. Research progress in precise molecular targeted therapy for advanced colorectal cancer [J]. Journal of International Oncology, 2024, 51(9): 601-605.
[8]	Li Zhiwei, Zhai Chunbao. Research progress on the anti-cancer effect of traditional Chinese medicine polyphenols on colorectal cancer [J]. Journal of International Oncology, 2024, 51(8): 526-531.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[12]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[13]	Liu Jiaqi, Wang Wenjun, Zhong Ping, Yang Min, Zhao Xinkai. Clinical efficacy and safety analysis of cetuximab combined with mFOLFOX6 chemotherapy in the treatment of advanced colorectal cancer patients [J]. Journal of International Oncology, 2024, 51(12): 763-768.
[14]	Chen Kunyan, Du Juan, Ji Yuwei, Gu Weiwei, Peng Hanzhi. Effects of irinotecan combined with XELOX regimen on immune status， intestinal microecology and prognostic risk in elderly patients with colorectal cancer [J]. Journal of International Oncology, 2024, 51(11): 690-695.
[15]	Chen Jie, Xu Hong, Chen Yutian. Role of tumor cell-derived exosomes in the pre-metastatic niche formation in colorectal cancer [J]. Journal of International Oncology, 2024, 51(10): 650-654.